Evidence map›Paper›PMID 39446151›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Mitigating effects of agmatine on myocardial infarction in rats subjected to isoproterenol.

Daniel Elieh-Ali-Komi, Fatemeh Yarmohammadi, Maryam Nezamabadi, Mohammad Reza Khirehgesh, Mitra Kiani, Khodabakhsh Rashidi, Ehsan Mohammadi-Noori, Nahid Salehi, Ahmad Reza Dehpour, Amir Kiani

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel Elieh-Ali-KomiInstitute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.ORCID 0000-0003-0546-5280
Fatemeh YarmohammadiMedical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-0552-8766
Maryam NezamabadiStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-5158-737X
Mohammad Reza KhirehgeshPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-6275-8007
Mitra KianiRegenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0009-0002-9127-9870
Khodabakhsh RashidiOils & Fats Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-8144-074X
Ehsan Mohammadi-NooriPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-1464-2691
Nahid SalehiCardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-4757-6336
Ahmad Reza DehpourDepartment of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8001-5565
Amir KianiPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. akiani@kums.ac.ir.ORCID 0000-0002-7802-2117

Funding

Kermanshah University of Medical Sciences 97438
6 · The paper itself

Abstract

Isoproterenol (ISO) usage is limited by its potential for cardiotoxicity. We sought to investigate the potential of agmatine in mitigating ISO-induced cardiotoxicity. Agmatine (100 mg/kg/day) was intraperitoneally administered to Wistar rats for 7 days in the presence or absence of cardiotoxicity induced by subcutaneous injection of ISO (85 mg/kg) on the sixth and seventh days. ECG parameters, lactate dehydrogenase (LDH), malondialdehyde (MDA), and creatinine phosphokinase (CPK) were investigated. Changes in cardiac tissue were also investigated using H&E staining. The heart weight/body weight ratio increased in ISO-treated rats. In the agmatine + ISO group, the increased heart rate observed in ISO-treated rats was reversed (317.2 ± 10.5 vs 452.2 ± 10.61, P < 0.001). Agmatine ameliorated the change in PR, RR, and ST intervals and the QRS complex, which was reduced by ISO. Treatment with saline, ISO, and agmatine had no significant effect on papillary muscle stimulation (P > 0.05). The administration of agmatine to ISO-receiving group could mitigate several parameters when compared to ISO-receiving group including increasing papillary muscle contraction (0.83 vs 0.71 N/M

Indexed as

AgmatineCardiotonic AgentsIsoproterenolMyocardial InfarctionAnimalsCardiotoxicityDisease Models, AnimalElectrocardiographyHeart RateL-Lactate DehydrogenaseMaleMalondialdehydeRatsRats, WistarAgmatineCardiotonic AgentsIsoproterenolL-Lactate DehydrogenaseMalondialdehydeAgmatineCardiotoxicityECGIsoproterenolPapillary muscle

Identifiers

PMID39446151

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.